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The present study compared the clinical and metabolic characteristics of latent
autoimmune diabetes in adults (LADA) with type 2 diabetes, as well as the residual
beta-cell function and progression to insulin treatment, over a 2-year follow-up
period, of antibody (Ab)-positive and Ab-negative patients who achieved tight
glycaemic control (HbA(1c) 7.0+/-0.8% and 6.5+/-0.9%, respectively, at the time of
entry into the study).
RESULTS:
Glutamic acid decarboxylase antibodies (GADA) and/or islet cell antibodies (ICA)
were detected in 10% of patients presenting with non-insulin-dependent diabetes.
Around half of Ab-positive patients required insulin treatment during the follow-up.
Ab-positive patients displayed lower stimulated C-peptide levels both at entry and
during the follow-up compared with Ab-negative patients, although no significant
decline in C-peptide levels was observed in either subgroup over two years.
Nevertheless, Ab-positive patients progressed more frequently to insulin treatment,
and stimulated C-peptide tended to decrease in LADA patients who subsequently
required insulin, whereas it remained stable in those who were non-insulin-
dependent. In those who progressed, the trend towards C-peptide decline persisted
even after starting insulin treatment.
CONCLUSION:
LADA patients demonstrate lower residual beta-cell function than do type 2
diabetes patients. However, those who achieve tight metabolic control do not
present with a rapid decline in beta-cell function. Further studies are needed to
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